Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Brankica Vasiljevic

NMC Royal Hospital DIP,UAE

Title: Stem Cell-based Therapy in Neonates

Biography

Biography: Brankica Vasiljevic

Abstract

Despite recent advances in neonatal intensive therapy, still is present significant morbidity associated with extreme prematurty that includes both short-term and long-term pulmonary,  neurologic and visual impairments. These complications of prematurity  not only affect the quality of life of these children in the rest of their lives, but can also cause numerous medical and economic burdens in the society.

No single therapy has proven to be effective in preventing or treating either developmental lung, brain and retinal injuries in preterm infants or the hypoxic-ischemic brain injury  in full-term infants.  Stem cell–based therapies are emerging as potential alternative treatment for such complex diseases (BPD, IVH, ROP and HIE) with multifactorial  etiologies.

Recently, various preclinical studies have shown that stem cell therapy significantly attenuates injuries in newborn animal models of BPD, HIE, IVH and ROP. 

Caution is warranted, however, because stem cell-based therapies for regenerative purposes represent innovation, mechanisms of action are still not completely understood, and standardization, clinical indications, timing and dosage are required to permit safe clinical translation of stem cell therapy in animal models for newborn infants in the near future,

No disclosure of any conflicts of interest.

References:

  • Spencer ND, Gimble JM, Lopez MJ. Mesenchymal stromal cells: past, present, and future. Vet Surg 2011;40:129-39.
  • Park WS, Sung SI, Ahn SY, Yoo HS, Sung DK, Im GH, et al. Hypothermia augments neuroprotective activity of mesenchymal stem cells for neonatal hypoxic-ischemic encephalopathy. PLoS One 2015;10:e.
  • Ahn SY, Chang YS, Sung DK, Sung SI, Yoo HS, Lee JH, et al. Mesenchymal stem cells prevent hydrocephalus after severe intraventricular hemorrhage. Stroke 2013;44:497-504.
  • Park WS, Sung SI, Ahn SY, Sung DK, Im GH, Yoo HS, et al. Optimal timing of mesenchymal stem cell therapy for neonatal intraventricular tricular hemorrhage. Cell Transplant 2016;25:1131-44.
  • Waszak P, Alphonse R, Vadivel A, Ionescu L, Eaton F, Thebaud B. Preconditioning enhances the paracrine efect of mesenchymal stem cells in preventing oxygen-induced neonatal lung injury in rats. Stem Cells Dev 2012;21:2789-97.
  • Chang YS, Ahn SY, Yoo HS, Sung SI, Choi SJ, Oh WI, et al. Mesenchymal stem cells for bronchopulmonary dysplasia: phase 1 dose-escalation clinical trial. J Pediatr 2014;164:966-72.
  • Stitt AW, O’Neill CL, O’Doherty MT. Archer DB, Gardiner TA. Vascular stem cells and ischaemic retinopathies. Prog Ret Eye Res 2011; 30:149e166e.